Evidence map›Paper›PMID 27898662›Full record

ArticlePLoS computational biology2016

Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle.

Peter Rashkov, Ian P Barrett, Robert E Beardmore, Claus Bendtsen, Ivana Gudelj

Abstract read
In one paragraph

Article in PLoS computational biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Bioadhesive Eudragit RLPharmaceutics · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter RashkovSchool of Biosciences, University of Exeter, Exeter, United Kingdom.
Ian P BarrettDiscovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.
Robert E BeardmoreSchool of Biosciences, University of Exeter, Exeter, United Kingdom.
Claus BendtsenDiscovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.
Ivana GudeljSchool of Biosciences, University of Exeter, Exeter, United Kingdom.ORCID http://orcid.org/0000-0003-3450-6854

Funding

Biotechnology and Biological Sciences Research Council BB/J010340/1Wellcome Trust
6 · The paper itself

Abstract

Many antimicrobial and anti-tumour drugs elicit hormetic responses characterised by low-dose stimulation and high-dose inhibition. While this can have profound consequences for human health, with low drug concentrations actually stimulating pathogen or tumour growth, the mechanistic understanding behind such responses is still lacking. We propose a novel, simple but general mechanism that could give rise to hormesis in systems where an inhibitor acts on an enzyme. At its core is one of the basic building blocks in intracellular signalling, the dual phosphorylation-dephosphorylation motif, found in diverse regulatory processes including control of cell proliferation and programmed cell death. Our analytically-derived conditions for observing hormesis provide clues as to why this mechanism has not been previously identified. Current mathematical models regularly make simplifying assumptions that lack empirical support but inadvertently preclude the observation of hormesis. In addition, due to the inherent population heterogeneities, the presence of hormesis is likely to be masked in empirical population-level studies. Therefore, examining hormetic responses at single-cell level coupled with improved mathematical models could substantially enhance detection and mechanistic understanding of hormesis.

Indexed as

Models, BiologicalAnimalsCell Physiological PhenomenaComputer SimulationHormesisHumansModels, ChemicalPhosphorylationProtein Kinase InhibitorsProtein KinasesProtein Kinase InhibitorsProtein Kinases

Identifiers

PMID27898662
PMCPMC5127489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.